TriSalus Life Sciences (TLSIW) Other Non-Current Liabilities (2022 - 2026)

TriSalus Life Sciences has reported Other Non-Current Liabilities for 5 years, with the latest figure at $9.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 10.39% year-over-year to $9.1 million; the trailing twelve-month figure through Mar 2026 stood at $9.1 million (up 10.39% YoY), and the FY2025 full-year result was $10.1 million, up 37.06% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $9.1 million, down from $10.1 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $18.6 million in Q4 2023, with the low at $369000.0 in Q4 2022.
• Historically, Other Non-Current Liabilities has averaged $8.6 million across 5 years, with a median of $8.0 million in 2024.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities jumped 4949.32% — and 2024, when it plunged 60.28%.
• TriSalus Life Sciences' Other Non-Current Liabilities stood at $369000.0 in 2022, then jumped by 4949.32% to $18.6 million in 2023, then sank by 60.28% to $7.4 million in 2024, then jumped by 37.06% to $10.1 million in 2025, then retreated by 10.54% to $9.1 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $9.1 million (Q1 2026), $10.1 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.